Dextroamphetamine
Dextroamphetamine is the dextrorotatory enantiomer of amphetamine and a central nervous system stimulant of the substituted phenethylamine class.citation needed Generally regarded as the prototypical stimulant, it exhibits more pronounced central nervous system effects than its mirror enantiomer, levoamphetamine. It is prescribed for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy1, and is also used recreationally as a euphoriant and cognitive enhancer.citation needed
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Duration
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
Dextroamphetamine produces a functional, clear-headed stimulant experience dominated by wakefulness, elevated mood, and enhanced concentration rather than sensory alteration. At therapeutic doses the effects center on increased alertness, initiative, self-confidence, and sociability, often accompanied by a mild euphoria that can give way to a mildly depressed mood as the effects wear off. It is the more centrally active enantiomer of amphetamine, and the character of the experience shifts sharply with dose: what is smooth and productive at lower doses becomes anxious, compulsive, and potentially psychotic at excessive doses.
Physical
The body feels energized, with reduced fatigue, improved reaction time, and pronounced appetite suppression. Dry mouth, increased heart rate, elevated blood pressure, teeth grinding, headache, and difficulty sleeping are the most commonly reported physical side effects.
Cardiovascular
Stimulation
The physical stimulation is energizing and performance-oriented rather than heavy or rushy at therapeutic doses.
Cognitive
The headspace is energetic and goal-oriented, marked by heightened alertness, concentration, initiative, and self-confidence, with improved cognitive control. Mood is elevated but can swing, and anxiety, irritability, grandiosity, and repetitive or obsessive behaviors become more likely as dose or frequency increases; large doses can impair rather than enhance cognition.
Emotional
The emotional tone is typically elevated and confident, but mood swings and anxious or irritable states are common, particularly at higher doses or during the offset.
Enhancements
High Dose
Excessive doses can precipitate a stimulant psychosis alongside panic, aggression, and compulsive behavior.
Pharmacology
Pharmacodynamics
Dextroamphetamine acts primarily as a monoamine releasing agent, increasing synaptic concentrations of dopamine, norepinephrine, and to a lesser extent serotonin.citation needed It is a potent full agonist of trace amine-associated receptor 1 (TAAR1), which inhibits monoamine transporter function and promotes neurotransmitter efflux, and also acts as a substrate of vesicular monoamine transporter 2 (VMAT2), displacing monoamines from synaptic vesicles into the cytosol. Transporter reversal can also occur independently of TAAR1 at high cytosolic monoamine concentrations. Additional activity includes antagonism at the alpha-1B adrenergic receptor.
Pharmacokinetics
Dextroamphetamine is well absorbed orally, with bioavailability typically around 90% that is unaffected by food intake.citation needed As a weak base (pKa 9.9), absorption varies with gastrointestinal pH, with alkaline conditions favoring uptake of the lipid-soluble free base form. Approximately 20% of circulating drug is bound to plasma proteins, and it readily distributes into most tissues, achieving high concentrations in cerebrospinal fluid and brain tissue. Metabolism occurs primarily through CYP2D6-mediated aromatic para-hydroxylation to 4-hydroxyamphetamine, with additional pathways involving dopamine β-hydroxylase (DBH), flavin-containing monooxygenase 3 (FMO3), and subsequent conjugation via sulfotransferase or glucuronosyltransferase. The elimination half-life is 9-11 hours at normal urine pH but is highly pH-dependent, ranging from approximately 7 hours in acidic urine to up to 34 hours in alkaline urine. Elimination occurs primarily via the kidneys, with 30–40% excreted unchanged at normal urinary pH.
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Amphetamines, Dopaminergic stimulants
Harm Potential
Addiction & Dependence
Psychological
HighDextroamphetamine has a high potential for abuse due to its dopaminergic rewarding properties affecting the mesocorticolimbic circuit. Recreational use frequently leads to compulsive use patterns, with individuals who self-administer high doses having high risk of developing addiction through ΔFosB overexpression in the nucleus accumbens.citation needed Therapeutic use at prescribed doses carries substantially lower addiction risk and may actually reduce risk of developing substance use disorders when used for ADHD treatment beginning in childhood.
Physical
ModeratePhysical dependence develops with chronic heavy use. When chronic high-dose users abruptly discontinue, approximately 88% experience a time-limited withdrawal syndrome within 24 hours of their last dose, persisting 3-4 weeks with a marked crash phase during the first week.citation needed Withdrawal symptoms include anxiety, drug craving, depressed mood, fatigue, increased appetite, movement changes, lack of motivation, and sleep disturbances. Discontinuation at therapeutic doses does not typically produce withdrawal symptoms.
Toxicity
Acute cardiovascular effects including hypertension, hypotension, tachycardia, arrhythmias, and Raynaud's phenomenon occur during use; however, large studies including a 2022 meta-analysis of nearly four million participants found no association between therapeutic amphetamine use and serious cardiovascular events (sudden death, heart attack, stroke) in any age group.citation needed
High doses in animal models cause dopaminergic neurotoxicity characterized by dopamine terminal degeneration and reduced transporter function;citation needed however, there is no evidence of direct neurotoxicity in humans at therapeutic doses, and long-term pharmaceutical use in ADHD patients appears to improve brain development and nerve growth.
Rapid muscle breakdown (rhabdomyolysis) may occur at excessive doses significantly exceeding typical recreational or therapeutic ranges.citation needed
Teratogenic and embryotoxic effects observed in mice at 41 times the maximum human dose but not in rat or rabbit studies; therapeutic use in humans does not appear to cause developmental abnormalities, though abuse during pregnancy poses fetal risks.citation needed
Psychosis Risk
Stimulant psychosis involving delusions, paranoia, and hallucinations can occur in heavy recreational users. Approximately 5-15% of users who develop amphetamine psychosis fail to recover completely.2 Psychosis rarely arises from therapeutic use, though individuals with pre-existing psychotic disorders may be at risk even at therapeutic doses. Antipsychotic medications have been shown to effectively resolve symptoms of acute amphetamine psychosis.2
Seizure Risk
Amphetamine may reduce seizure threshold as a side effect.3 Convulsions are primarily associated with severe overdose and fatal poisoning rather than typical use. Contraindicated in individuals with seizure disorders.
History & Culture
Synthesis and Early Development
Racemic amphetamine was first synthesized in Berlin in 1887 by the Romanian chemist Lazăr Edeleanu, who prepared the compound under the chemical name "phenylisopropylamine."citation needed The substance remained relatively obscure for several decades until the pharmaceutical company Smith, Kline…
Legality
International
UN Convention on Psychotropic Substances 1971: scheduled
By Country
South KoreaProhibited
ChileRestricted
SingaporeRestricted
SlovakiaRestricted
South AfricaRestricted
United StatesPrescription only
ArgentinaPrescription only
AustriaPrescription only
CanadaPrescription only
ColombiaPrescription only
DenmarkPrescription only
IrelandPrescription only
ItalyPrescription only
PortugalPrescription only
SpainPrescription only
SwedenPrescription only
SwitzerlandPrescription only
United KingdomPrescription only
FranceStupéfiantReferences
Source Pages
Citations
- Zenzedi – dextroamphetamine sulfate tablet. (n.d.). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6394df5-f2c9-47eb-b57e-f3e9cfd94f84123
- Steven J Shoptaw, Uyen Kao, & Walter Ling. (2009). Treatment for amphetamine psychosis. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd003026.pub312
- Dexedrine spansule- dextroamphetamine sulfate capsule, extended release. DailyMed (10 January 2022). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc717b9b-22ea-4c60-a1d4-ee38a40bce78123
- Dextroamphetamine; Dextroamphetamine Saccharate; Amphetamine; Amphetamine Aspartate Drug Usage Statistics, United States, 2014 - 2023. ClinCalc (n.d.). https://clincalc.com/DrugStats/Drugs/DextroamphetamineDextroamphetamineSaccharateAmphetamineAmphetamineAspartate1
- Preuss CV, Kalava A, & King KC. (2024). Controlled Substance Act. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK574544/1
- Ley N.º 19.303. anmat.gob.ar (n.d.). https://www.anmat.gob.ar/webanmat/Legislacion/Medicamentos/ley19303.pdf1
- Ley N.º 19.303. argentina.gob.ar (n.d.). https://www.argentina.gob.ar/normativa/nacional/ley-19303-20966/actualizacion1
- Ley N.º 19.303. boletinoficial.gob.ar (n.d.). https://www.boletinoficial.gob.ar/detalleAviso/primera/338915/20260302?anexos=11
- Ley N.º 19.303. argentina.gob.ar (n.d.). https://www.argentina.gob.ar/normativa/nacional/ley-23737-138/actualizacion1
- Therapeutic Goods (Poisons Standard—February 2026) Instrument 2026, Schedule 8. legislation.gov.au (n.d.). https://www.legislation.gov.au/F2026L00060/latest/text1
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes7 human edits · latest
Times are UTCNewest first
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the Dextroamphetamine article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.